Clinical trial • Infectious Disease
Transfer Factor TFI for Recurrent respiratory tract infections | Recurrent urinary tract infections | Recurrent herpetic infections
Clinical trial of Transfer Factor TFI for Recurrent respiratory tract infections | Recurrent urinary tract infections | Recurrent herpetic infections.
Overview
- Trial Therapeutic Area
- Infectious Disease
- Trial Disease
- Recurrent respiratory tract infections | Recurrent urinary tract infections | Recurrent herpetic infections
Key dates
- Initial CTIS Submission Date
- 13-09-2024
- First CTIS Authorization Date
- 08-01-2025
Trial design
Randomised, placebo (placebo-controlled); dose and schedule not specified trial across 3 sites in Czechia.
- Randomised
- Yes
- Comparator
- Placebo (placebo-controlled); dose and schedule not specified
- Target Sample Size
- 100
- Trial Duration For Participant
- 183
Eligibility
Recruits 100 Vulnerable population selected; no details on consent or assent handling provided in the record..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent handling provided in the record.
Recruitment
- Planned Sample Size
- 100
- Recruitment Window Months
- 13
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 100
Czechia
- Earliest CTIS Part Ii Submission Date
- 09-09-2024
- Latest Decision Or Authorization Date
- 08-01-2025
- Processing Time Days
- 121
- Number Of Sites
- 3
- Number Of Participants
- 100
Sites
- Site Name
- Nemocnice Na Homolce
- Department Name
- Oddělení Klinické biochemie, hematologie a imunologie
- Contact Person Name
- Miroslav Průcha
- Contact Person Email
- Miroslav.Prucha@homolka.cz
- Site Name
- Fakultni Nemocnice Ostrava
- Department Name
- Ustav klinicke imunologie a alergologie
- Contact Person Name
- Irena Krcmova
- Contact Person Email
- Irena.krcmova@fnhk.cz
- Site Name
- Fakultni Nemocnice Hradec Kralove
- Department Name
- . Depart. Allergology and Clinical Immunology
- Contact Person Name
- Jaromir Bystron
- Contact Person Email
- jaromir.bystron@fno.cz
Sponsor
Primary sponsor
- Full Name
- Aumed a.s.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Czechia
Investigational products
- Investigational Product Name
- Transfer Factor TFI
Related trials
Other published trials that may interest you.
- Conditioned medium from a co-culture of M2-macrophages and fat-derived mesenchymal cells for Acute respiratory distress syndrome (ARDS) | SARS-CoV-2 infection | Influenza A infection | Influenza B infection | Respiratory syncytial virus (RSV) infection
- ACICLOVIR for Recurrent herpes labialis | Herpes simplex labialis
- AMIKACIN SULFATE for Sepsis | Neutropenia
- LENACAPAVIR, ISLATRAVIR for HIV-1 infection
- piperacillin sodium, tazobactam sodium for Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae severe infection